PFE · Earnings call · 2026Q3T · Full report

China Market Access

PFIZER INC · 2026-11-03 · Importance 34 · Surprise 42

Pfizer said it introduced ecnoglutide in China at the end of April 2026 and received approval for its type 2 diabetes indication at the end of October, opening access to hospital and, under local regulations, e-commerce channels. Management said the product had passed the National Reimbursement Drug List (NRDL) committees in June and that a final review was expected by the end of November 2026. Pfizer said reimbursement access, together with the new indication, would support the start of market penetration; no financial impact was quantified.

Key facts

• Pfizer passed China's NRDL committees for ecnoglutide in June and expected a final review by the end of November 2026.
• Pfizer said it introduced ecnoglutide in China at the end of April 2026 and received approval for its type 2 diabetes indication since the end of October.
• Pfizer said ecnoglutide received approval for its type 2 diabetes indication, opening the hospital and, under local regulations, e-commerce channels.
• Pfizer is learning about the China market for obesity products and considers that market suited to its capabilities.